Accession Therapeutics Marks Milestone with TROCPT-01 Clinical Trial Initiation in Cancer Treatment

Accession Therapeutics Initiates Phase 1 Trial for TROCEPT-01

Accession Therapeutics Limited, a pioneering company in the biopharmaceutical arena, has taken a significant step towards revolutionizing cancer treatment. The company recently announced the initiation of its Phase 1 clinical trial for TROCEPT-01 (ATTR-01), their flagship cancer immunotherapy. This momentous milestone was marked by successfully dosing the first patient, signaling potential advancements in the treatment of solid tumors.

TROCEPT-01 is being heralded as a first-in-class, tumor-activated viral immunotherapy. It is engineered to selectively produce a clinically validated checkpoint inhibitor within tumor sites after systemic delivery. This innovative mechanism targets the αvβ6 integrin found on epithelial tumors, allowing for optimized therapeutic effects while sparing healthy tissue from harm. Preclinical evaluations have shown substantial antitumor activity across various solid tumor models, leading to high expectations for its clinical application in treating aggressive cancers.

The ongoing ATTEST trial is designed as an open-label, dose-escalation and expansion study aimed at assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of TROCEPT-01 in patients with advanced carcinomas who have previously undergone treatment. The trial is being conducted at prestigious clinical sites throughout the UK, with plans for expansion into Spain as the study progresses.

Professor Adel Samson, who specializes in Cancer Medicine and Immunotherapy at the Leeds University School of Medicine and leads the ATTEST study, expressed immense enthusiasm about the trial. He stated, "As a clinician, I am very excited about the potential of TROCEPT-01 (ATTR-01) to significantly boost clinical response rates through localized, tumor-focused production of anti-cancer drugs. This treatment targets solid tumors where improved outcomes are critically needed."

Accession Therapeutics' CEO, Bent Jakobsen, PhD, emphasized the significance of this trial in the company’s journey. "Dosing the first patient in TROCEPT-01’s clinical trial is pivotal for Accession Therapeutics and showcases the incredible dedication of our team and collaborators. Our TROCEPT platform allows us to create unique, versatile drugs directly within cancer cells, paving the way for transformative outcomes for patients."

Additionally, Professor Hardev Pandha, the company’s Medical Director, highlighted the novel nature of TROCEPT-01 in tackling hard-to-treat cancers. He revealed that they anticipate observing the virus’s efficacy in reaching tumors through systemic administration, with localized drug production within those tumors. The primary objective of the ATTEST trial is to establish the therapy’s safety profile while identifying early efficacy signals that could benefit patients with limited treatment options.

Accession Therapeutics, founded in 2021, has meticulously focused on developing a new class of tumor-targeted immunotherapies via its proprietary TROCEPT technology. This innovative platform enables localized creation of therapeutic proteins within tumors, aiming to minimize systemic exposure and thereby offer enhanced safety and efficacy compared to conventional immuno-oncology approaches. With USD $70 million raised to date, the company is set on advancing its groundbreaking technology and therapies.

TROCEPT-01 (ATTR-01), the leading therapy in their pipeline, encapsulates the company’s vision by delivering a genetically encoded immune checkpoint inhibitor (anti-PD-L1) directly to cancer cells. This mechanism promotes an amplified anti-tumor response while reducing the risk of adverse events seen with traditional immune therapies. Administered intravenously, TROCEPT-01 presents a promising new avenue for treating a wide array of solid tumors, striving to better therapeutic outcomes in an area where existing treatments often fall short.

For further details about this groundbreaking study, visit Accession Therapeutics’s website or consult the UK Clinical Study Registry for in-depth information.

For media inquiries, contact:
Victoria Foster Mitchell
Email: [email protected]
Stephanie Bewick - Chief Business Officer
Email: [email protected]